Mine Ün, Özge Çoşkun

Istanbul Aydın University Medical Faculty, Istanbul, Turkey

Keywords: Carcinoma, diarrhea, irinotecan


Although there are diagnosis and treatment methods for cancer, treatment methods for metastatic cancers are limited. Therefore, new treatments for metastatic cancer are being investigated. Antibody drug conjugates (ADCs) are a new group of drugs that enable highly toxic drugs to be targeted. Sacituzumab govitecan is a second-generation antibody drug conjugate that is promising with its results in many cancer treatment trials.

Cite this article as: Ün M, Çoşkun Ö. Sacituzumab Govitecan and Treatment Area. JEB Med Sci 2020;1(2):62-64.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.